Whilst political arbitration remains necessary, multi-year frameworks present legitimate industry demands requiring careful implementation.
In Conversation
Our mission is clear: to preserve and strengthen ‘Made in France’ pharmaceuticals.
Plasma collection is not a secondary concern – it is a strategic imperative.
We build the machines others can’t—or won’t.
We are not just imagining a world without the fear of cancer; we are actively building it.
This holistic approach creates value across the entire healthcare ecosystem whilst addressing some of society's most pressing health challenges.
The evolution from vendor-customer relationships to strategic partnerships represents one of the most significant transformations I have witnessed.
The combination of our substantial capital investment and regulatory approval creates a strong foundation for growth in drug product manufacturing.
Equity for rare disease patients is a question of prioritisation, not affordability.
Lysates are important in today’s changing world where we face new challenges - increasingly burdened by chronic conditions and antimicrobial resistance...
We have deliberately pursued a value engineering approach, combining cost-effective manufacturing with uncompromising quality specifications.
I am confident that the foundations of our strong performance, clear strategic path, and honest leadership, position us to become one of Europe’s leading API manufacturers.
